Zydus Lifesciences Secures Tentative USFDA Nod for Breakthrough Diabetes Combination Tablets

Zydus Lifesciences Limited has achieved a notable regulatory milestone with the US Food and Drug Administration granting tentative approval for its Empagliflozin and Linagliptin combination tablets in 10 mg/5 mg and 25 mg/5 mg strengths. These tablets, equivalent to the US Reference Listed Drug Glyxambi, are designed to help control blood sugar levels in adults with type 2 diabetes alongside diet and exercise.

Tentative approval signals that the product meets USFDA standards but awaits patent or exclusivity considerations before final marketing authorization. This development expands Zydus’ presence in the highly competitive US diabetes treatment landscape, reflecting its strong capabilities in complex generics.

The combination therapy targets two key mechanisms in blood sugar regulation: Empagliflozin acts through sodium-glucose co-transporter inhibition, while Linagliptin inhibits dipeptidyl peptidase-4, improving glycemic control with enhanced patient compliance.

Key Highlights:

USFDA tentative approval for Empagliflozin and Linagliptin tablets (10 mg/5 mg and 25 mg/5 mg).

Tablets are generic equivalents of Glyxambi, used for type 2 diabetes management.

Approval marks a strategic advance into the US diabetes therapies market.

Combines two complementary anti-diabetic agents for effective glycemic control.

Aligns with Zydus Lifesciences’ global expansion and innovation strategy in complex generics.

Paves way for future commercialization pending patent/exclusivity clearance.

Sources: Zydus Lifesciences official release, NSE India archives, FirstWord Pharma, Express Pharma​